Status:
COMPLETED
Effects of Moxaverine and Placebo on Ocular Blood Flow
Lead Sponsor:
Medical University of Vienna
Conditions:
Regional Blood Flow
Ocular Physiology
Eligibility:
All Genders
18-35 years
Phase:
PHASE2
Brief Summary
A number of common eye diseases such as retinal artery and vein occlusion, diabetic retinopathy, age-related macular degeneration, glaucoma and anterior ischemic optic neuropathy are associated with o...
Eligibility Criteria
Inclusion
- Men and women aged between 18 and 35 years, nonsmokers
- Body mass index between 15th and 85th percentile
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
- Normal ophthalmic findings, ametropy \< 3 dpt.
Exclusion
- Regular use of medication, abuse of alcoholic beverages or drugs, participation in a clinical trial in the 3 weeks preceding the study
- Treatment in the previous 3 weeks with any drug
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs
- Blood donation during the previous 3 weeks
- Ametropy \>= 3 dpt
- Acute gastric bleeding, massive cerebral hemorrhage related to stroke
- Women: pregnancy or lactation
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00709423
Start Date
March 1 2007
End Date
May 1 2007
Last Update
July 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clincal Pharmacology, Medical University of Vienna
Vienna, Austria, 1090